PMID- 26918950
OWN - NLM
STAT- MEDLINE
DCOM- 20170310
LR  - 20170310
IS  - 1751-2441 (Electronic)
IS  - 1751-2433 (Linking)
VI  - 9
IP  - 6
DP  - 2016 Jun
TI  - A meta-analysis of apremilast on psoriatic arthritis long-term assessment of 
      clinical efficacy (PALACE).
PG  - 799-805
LID - 10.1586/17512433.2016.1159130 [doi]
AB  - The aim of this article was to assess the efficacy and safety of apremilast in 
      treatment of psoriatic arthritis (PsA) with meta-analysis method. We included 
      four randomized clinical trials identified from MEDLINE, EMBASE, Cochrane 
      Library, "ISRCTN Register" and "ClinicalTrials.gov" which compared apremilast 
      with placebo. The meta-analysis was performed by the software of Review Manager, 
      version 5.2. Apremilast was associated with significantly higher proportion of 
      patients who achieved ACR20 at week 16 (in apremilast 20 mg subgroup, odds ratio 
      [OR]= 2.04, 95% confidence interval [Cl] 1.58-2.63, P<0.00001; in apremilast 30 
      mg subgroup, OR=2.53, 95%Cl 1.96-3.25, P<0.00001) and significantly higher scores 
      of Health Assessment Questionnaire-Disability Index (in apremilast 20 mg 
      subgroup, WMD=-0.11, 95%Cl -0.16~-0.06, P<0.0001; in apremilast 30 mg subgroup, 
      WMD=-0.16, 95%Cl -0.21~-0.11, P<0.00001). Apremilast was as safe as placebo in 
      terms of serious adverse events (AEs). The AEs occurred in participants with 
      apremilast were mild and well tolerated during treatment. Apremilast can be used 
      in treatment of PsA with lower costs, oral availability and well tolerated. But 
      the long-term benefit and safety of apremilast should be further investigated.
FAU - Qu, Xiaoyu
AU  - Qu X
AD  - a Department of Pharmacy , The First Hospital of Jilin University , Changchun , 
      PR China.
FAU - Zhang, Sixi
AU  - Zhang S
AD  - a Department of Pharmacy , The First Hospital of Jilin University , Changchun , 
      PR China.
FAU - Tao, Lina
AU  - Tao L
AD  - a Department of Pharmacy , The First Hospital of Jilin University , Changchun , 
      PR China.
FAU - Song, Yanqing
AU  - Song Y
AD  - a Department of Pharmacy , The First Hospital of Jilin University , Changchun , 
      PR China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20160408
PL  - England
TA  - Expert Rev Clin Pharmacol
JT  - Expert review of clinical pharmacology
JID - 101278296
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 4Z8R6ORS6L (Thalidomide)
RN  - UP7QBP99PN (apremilast)
SB  - IM
MH  - Administration, Oral
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Arthritis, Psoriatic/*drug therapy/physiopathology
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Thalidomide/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Meta-analysis
OT  - apremilast
OT  - efficacy
OT  - psoriatic arthritis
OT  - safety
EDAT- 2016/02/27 06:00
MHDA- 2017/03/11 06:00
CRDT- 2016/02/27 06:00
PHST- 2016/02/27 06:00 [entrez]
PHST- 2016/02/27 06:00 [pubmed]
PHST- 2017/03/11 06:00 [medline]
AID - 10.1586/17512433.2016.1159130 [doi]
PST - ppublish
SO  - Expert Rev Clin Pharmacol. 2016 Jun;9(6):799-805. doi: 
      10.1586/17512433.2016.1159130. Epub 2016 Apr 8.